Arbutus Biopharma Corporation

ABUS

$4.85

Name : Arbutus Biopharma Corporation

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $960,812,864.00

EPSttm : 0.79

Arbutus Biopharma Corporation

$4.85

0.61%

$0.03

ABUS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

11.72

Margin Of Safety %

Put/Call OI Ratio

0.96

EPS Next Q Diff

EPS Last/This Y

1.2

EPS This/Next Y

-1.14

Price

4.85

Target Price

5.5

Analyst Recom

Performance Q

5.9

Upside

109.1%

Beta

0.76

Ticker: ABUS

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-08-28	ABUS	5.05	0.81	0.12	21481
2026-08-31	ABUS	5.07	0.80	2.11	21728
2026-09-02	ABUS	5.09	0.97	0.01	24262
2026-09-03	ABUS	5.11	0.96	0.00	24389
2026-09-04	ABUS	5.15	0.92	0.00	25037
2026-09-08	ABUS	5.18	0.92	0.00	25050
2026-09-09	ABUS	5.16	0.91	9.00	25063
2026-09-10	ABUS	5.12	0.91	0.06	25070
2026-09-11	ABUS	5.12	0.91	0.54	25173
2026-09-14	ABUS	5.12	0.91	0.98	25179
2026-09-15	ABUS	5.06	0.92	0.00	27187
2026-09-16	ABUS	5.04	0.93	2.83	31218
2026-09-17	ABUS	5.07	0.94	0.00	32381
2026-09-18	ABUS	5	0.91	0.98	31733
2026-09-21	ABUS	4.99	0.80	1.60	34896
2026-09-22	ABUS	5.01	0.80	1.00	35006
2026-09-23	ABUS	4.86	0.91	1.05	76581
2026-09-24	ABUS	4.88	0.95	1.13	111596
2026-09-25	ABUS	4.85	0.96	1.01	125368
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-08-28	ABUS	5.09	-	-	1.03
2026-08-31	ABUS	5.07	-	-	1.03
2026-09-01	ABUS	5.09	-	-	1.03
2026-09-02	ABUS	5.09	-	-	1.03
2026-09-03	ABUS	5.13	-	-	1.03
2026-09-04	ABUS	5.14	-	-	1.03
2026-09-08	ABUS	5.17	-	-	1.03
2026-09-09	ABUS	5.16	-	-	1.03
2026-09-10	ABUS	5.12	-	-	1.03
2026-09-11	ABUS	5.12	-	-	1.03
2026-09-14	ABUS	5.12	-	-	1.03
2026-09-15	ABUS	5.06	-	-	1.03
2026-09-16	ABUS	5.06	-	-	1.03
2026-09-17	ABUS	5.06	-	-	1.03
2026-09-18	ABUS	5.01	-	-	1.03
2026-09-21	ABUS	4.99	-	-	1.03
2026-09-22	ABUS	5.01	-	-	1.03
2026-09-23	ABUS	4.86	-	-	1.03
2026-09-24	ABUS	4.88	-	-	1.03
2026-09-25	ABUS	4.85	-	-	1.03
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-08-28	ABUS	0.00	-0.15	11.73
2026-08-31	ABUS	0.00	0.15	11.73
2026-09-01	ABUS	0.00	0.15	11.73
2026-09-02	ABUS	0.00	0.15	11.73
2026-09-03	ABUS	0.00	0.15	11.73
2026-09-04	ABUS	0.00	0.15	11.73
2026-09-08	ABUS	0.00	0.57	11.71
2026-09-09	ABUS	0.00	0.57	11.71
2026-09-10	ABUS	0.00	0.57	11.71
2026-09-11	ABUS	0.00	0.57	12.00
2026-09-14	ABUS	0.00	0.57	12.00
2026-09-15	ABUS	0.00	0.57	12.00
2026-09-16	ABUS	0.00	0.57	12.00
2026-09-17	ABUS	0.00	0.57	12.00
2026-09-18	ABUS	0.00	0.57	11.99
2026-09-21	ABUS	0.00	0.58	11.99
2026-09-23	ABUS	0.00	0.58	11.99
2026-09-24	ABUS	0.00	0.58	11.99
2026-09-25	ABUS	0.00	0.58	11.72
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.03

Avg. EPS Est. Next Quarter

-0.03

Insider Transactions

Institutional Transactions

0.58

Beta

0.76

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

25.4

Max Drawdown 5-Year %

-63.4

Target Price

5.5

P/E

6.19

Forward P/E

PEG

P/S

5.29

P/B

3.7

P/Free Cash Flow

EPS

0.78

Average EPS Est. Cur. Y

1.03

EPS Next Y. (Est.)

-0.11

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

84.23

Relative Volume

2.69

Return on Equity vs Sector %

32.9

Return on Equity vs Industry %

52.5

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

◆ ABUS Healthcare

$4.85

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

6/20

Pullback

24/25

Volume

3/15

Valuation

7/20

TP/AR

2/10

Options

4/10

RSI

40.8

Range 1M

19.6%

Sup Dist

0.4%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

5/25

Growth

12/30

Estimates

3/20

Inst/Vol

8/15

Options

2/10

EPS Yr

535.3%

EPS NY

-110.8%

52W%

71%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +13.4% upside

Quality

30/30

Valuation

5/30

Growth

6/25

Stability

8/10

LT Trend

2/5

Upside

+13.4%

Quality

ABUS — P/E HistoricalBiotechnology

Arbutus Biopharma Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 19

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

ABUS

Latest News

—

Caricamento notizie per ABUS…

stock quote shares ABUS – Arbutus Biopharma Corporation Stock Price stock today

news today ABUS – Arbutus Biopharma Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch ABUS – Arbutus Biopharma Corporation yahoo finance google finance

stock history ABUS – Arbutus Biopharma Corporation invest stock market

stock prices ABUS premarket after hours

ticker ABUS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: ABUS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y